Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction ...

Amgen's Repatha (evolocumab) has shown benefit in a long-term study in reducing cardiovascular incidents in patients without ...

Amgen announced the launch of its direct-to-patient program providing eligible patients discounted pricing for evolocumab, a ...

GoodRx (GDRX) announced the availability of Repatha, a cholesterol-lowering therapy, at a significantly reduced cash price. Patients can use ...

Findings from the Phase III VESALIUS-CV study reinforce the cholesterol-lowering benefit of Repatha in high-risk patients ...

Amgen AMGN announced that the FDA has approved its PCSK9 inhibitor, Repatha for different forms of familial hypercholesterolemia (FH) in pediatric patients. The first approval is for Repatha as an ...

Previously, Repatha was indicated to reduce the risk of MACE in patients with established cardiovascular disease. The Food and Drug Administration (FDA) has expanded the approval of Repatha ® ...

Amgen recently received an expanded FDA approval for Repatha®, broadening its use for adults at risk of major cardiovascular events. During the same quarter, the company reported significant earnings ...